A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects with Advanced Non-Small Cell Lung Cancer
This study is a multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic, immunogenicity, and antitumor activity of MEDI4736 in combination with tremelimumab in adult subjects with advanced NSCLC.
MEDI4736 is an anti-PD-L1 monoclonal antibody. Tremelimumab is an anti-CTLA4 monoclonal antibody. Both are given by intravenous infusion.
To be eligible for this study, patients must:
- Have advanced non-small cell lung cancer
- Have an ECOG status of 0 or 1.
- Be age 18 or older.
For more information about this study and to inquire about eligibility, please contact Dr. Jamie Chaft at 646-888-4545.